Comparison of endothelialization and neointimal formation with stents coated with antibodies against CD34 and vascular endothelial-cadherin
| Autor: | Yoon Sik Lee, Hyun Jai Cho, Hyo-Soo Kim, San Kyeong, Han Mo Yang, Hyun Ju Cho, Jin Hur, Baek Kyung Kim, Won Seok Choe, Young Chan Kim, Woo Hyun Lim, Chan Koo Kang, Joo Myung Lee, Won Woo Seo, Khee Dong Eom |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Neointima
medicine.medical_specialty Materials science medicine.medical_treatment Biophysics Urology CD34 Antigens CD34 Bioengineering Endothelial progenitor cell Antibodies Biomaterials Coated Materials Biocompatible Restenosis Antigens CD In vivo medicine Humans Endothelium cardiovascular diseases Progenitor cell Cell Proliferation Stem Cells Endothelial Cells Stent Cadherins equipment and supplies medicine.disease Mechanics of Materials Leukocytes Mononuclear Ceramics and Composites Stents VE-cadherin Biomedical engineering |
| Zdroj: | Biomaterials. 33:8917-8927 |
| ISSN: | 0142-9612 |
| DOI: | 10.1016/j.biomaterials.2012.08.066 |
| Popis: | Vascular endothelial-cadherin (VE-cadherin) is exclusively expressed on the late endothelial progenitor cells (EPC). Therefore, VE-cadherin could be an ideal target surface molecule to capture circulating late EPC. In the present study, we evaluated whether anti-VE-cadherin antibody-coated stents (VE-cad stents) might accelerate endothelial recovery and reduce neointimal formation more than anti-CD34 antibody-coated stents (CD34 stents) through the superior ability to capture the late EPC. The stainless steel stents were coated with anti-human VE-cadherin antibodies or anti-human CD34 antibodies under the same condition. In vitro, VE-cad stents showed higher number of adhering EPC (823.6 ± 182.2 versus 379.2 ± 137.2 cells per HPF, p < 0.001). VE-cad stents also demonstrated better specific capturing of cells with endothelial lineage markers than CD34 stents did in flow cytometric analysis. VE-cad stents showed more effective re-endothelialization after 1 h, 24 h, and 3 days in vivo. At 42 days, VE-cad stents demonstrated significantly smaller neointima area (0.92 ± 0.38 versus 1.24 ± 0.41 mm(2), p = 0.002) and significantly lower PCNA positive cells in neointima (1684.8 ± 658.8/mm(2) versus 2681.7 ± 375.1/mm(2), p = 0.008), compared with CD34 stents. In conclusion, VE-cad stents captured EPC and endothelial cells more selectively in vitro, accelerated re-endothelialization over stents, and reduced neointimal formation in vivo, compared with CD34 stents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect